RAC
Click for more information
5.59% $1.70 race oncology ltd

Ann: Zantrene AML trial in Israel advances to Phase 2, page-110

  1. EWexplorer
    5,709 Posts.
    lightbulb Created with Sketch. 1816
    clock Created with Sketch.
    14/07/23
    07:34
    Post #: 68780920
    Some may remember ...

    https://stocklight.com/stocks/au/health-care/asx-rac/race-oncology?media_id=24728

    Peter Molloy: Our current share price indicates a valuation of only AUD$11 million, and yet, within the next six to nine months, we could have a phase III oncology asset in human trials. There is a big gap there in potential valuation, and upside for Race Oncology (ASX:RAC) investors.

    Haha ... this is where DrT made his entry shortly after they failed to meet DrM's objectives and were running out of money and direction.

    The momentum is gathering. I assume AML is worth an SP of $5, so the Sheba work will probably confirm a new ATH. But more importantly it will validate the efficacy of the drug, once and for all, and start the run into Cardio, FTO in earnest.

    The other thing I'm always conscious of ... Bisantrene's roots.

    History[]

    Bisantrene was developed by during the 1970s, a subsidiary of American Cyanamid, as a less cardiotoxic alternative to anthracyclines. Across the 1980s and early 1990s, over 40 clinical trials were conducted using Bisantrene. The National Cancer Institute (NCI)] undertook a large scale trial using Bisantrene under the name "Orange Crush", including a range of preclinical trials which found bisantrene to be inactive when taken orally, though was found to be efficacy towards some cancer cells intravenous, intraperitoneal, or subcutaneous.[]

    In the 1980s, forty-four patients with metastatic breast cancer who had undergone extensive combination chemotherapy with doxorubicin and had failed to respond to the combination, were treated with bisantrene. From 40 patients that were evaluated, 9 showed a partial response, and 18 showed the cancer was not progressive but stabilised.[]

    Bisantrene was approved for human medical use in France in 1990 to target Acute Myeloid Leukemia (AML) cancers.[]

    It has undergone 46 Phase II trials with 1,800 patients to test its efficacy against fighting cancer cells.[]

    The drug was delisted in the early 1990s due to a series of pharmaceutical mergers and acquisitions.[

    RAC Price at posting: $1.53 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 27  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?
right-arrow Created with Sketch.
AHK Ark Mines defines significant exploration target at Sandy Mitchell rare earths project
right-arrow Created with Sketch.
STN Saturn’s stars have aligned for the gold explorer’s Apollo Project
right-arrow Created with Sketch.
CUV British study shows Clinuvel drug effective on DNA of UV-damaged skin
right-arrow Created with Sketch.
A1M Swagman shoot proves plentiful for AIC, with Cu beyond 3% close to Eloise
right-arrow Created with Sketch.
SXE SCEE boosts Synergy deal by $50M for Collie battery project
right-arrow Created with Sketch.
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.70 		Change
0.090(5.59%) 		Mkt cap ! $289.5M
Open High Low Value Volume
$1.60 $1.76 $1.59 $142.7K 84.97K

Buyers (Bids)

No. Vol. Price($)
2 17175 $1.70
 

Sellers (Offers)

Price($) Vol. No.
$1.77 6060 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.